New Delhi Breaking its silence over the death of 66 children in The Gambia after consuming cough syrup manufactured by them, Haryana-based Maiden Pharmaceuticals on Saturday said the product samples have been prepared by Central Drugs Standard Control Organization (CDSCO) officials and results are awaited
“The samples have been taken by the officials of CDSCO and we are awaiting the results and the matter is already under investigation and consideration,” the company said in a statement.
It said, “Government agencies visited the firm on October 1, 3, 6 and 7 respectively and samples were taken by CDSCO in the presence of our Director along with all relevant documents.”
The drugmaker said it has been in the pharmaceutical sector for more than three decades and needs approval to export the products. The firm also clarified that it is not selling any product in the domestic market.
“We have valid drug approval for export of PUC and we are not selling anything in the domestic market, hence it is for export only,” the statement said. companies.
According to the World Health Organization (WHO), Maiden Pharmaceuticals is under investigation for allegedly supplying contaminated cough syrups to The Gambia.
WHO Director-General Dr Tedros Adhanom Ghebreyesus issued an alert on Wednesday against four cough and cold syrups made by Maiden, saying it could be linked to the deaths of children in The Gambia.
“So far, contaminated products have been found only in The Gambia, but the products have been distributed to other countries. WHO advises all countries to detect and remove these products,” said Dr. Tedros.
catch all corporate news And updates on Live Mint. download mint news app to receive daily market update & Live business News,